DrugPatentWatch Database Preview

ASENDIN Drug Profile

« Back to Dashboard

When do Asendin patents expire, and what generic alternatives are available?

Asendin is a drug marketed by Lederle and is included in one NDA.

The generic ingredient in ASENDIN is amoxapine. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxapine profile page.

Summary for ASENDIN

US Patents:	0
Applicants:	1
NDAs:	1
Bulk Api Vendors:	79
Patent Applications:	4,218
Formulation / Manufacturing:	see details
DailyMed Link:	ASENDIN at DailyMed

Medical Subject Heading (MeSH) Categories for ASENDIN

Adrenergic Uptake Inhibitors

Antidepressive Agents, Second-Generation

Dopamine Antagonists

Neurotransmitter Uptake Inhibitors

Serotonin Uptake Inhibitors

Synonyms for ASENDIN

(E)-2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine

028A445

13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,9,12,14-heptaene

13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene

13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0;{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene

14028-44-5

2-Chlor-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepin

2-Chloro-11-(1-piperazinyl)- dibenz[b,f][1,4]oxazepine

2-Chloro-11-(1-piperazinyl)-dibenz[b,f][1,4]oxazepine

2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine

2-Chloro-11-(1-piperazinyl)dibenz[b,f]-1,4-oxazepine

2-Chloro-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepine

2-Chloro-11-(1-piperazinyl)dibenzo[b,f][1,4]oxazepine

2-Chloro-11-(1-piperazinyl)dibenzo[b,f][1,4]oxazepine #

2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine

2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine

8-chloranyl-6-piperazin-1-yl-benzo[b][1,4]benzoxazepine

8-chloro-6-(1-piperazinyl)benzo[b][1,4]benzoxazepine

8-chloro-6-piperazin-1-yl-benzo[b][1,4]benzoxazepine

8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine

8-chloro-6-piperazin-1-ylbenzo[b][1,5]benzoxazepine

A-129

A807639

AB00052421_14

AB00052421_15

AB00052421-13

ABP000992

AC-5495

AC1L1D2U

AKOS015895092

Amoxan

Amoxapin

Amoxapina

Amoxapina [INN-Spanish]

amoxapine

Amoxapine (JP17/USP/INN)

Amoxapine [USAN:BAN:INN:JAN]

Amoxapine [USAN:USP:INN:BAN:JAN]

Amoxapine, 1.0 mg/mL in methanol, certified reference material

Amoxapine, Pharmaceutical Secondary Standard; Certified Reference Material

Amoxapine, United States Pharmacopeia (USP) Reference Standard

Amoxapinum

Amoxapinum [INN-Latin]

Amoxepine

amoxipine

AN-10914

Ascendin

Asendin (TN)

Asendis

BC657161

BDBM22870

BG0035

BPBio1_000094

BRD-K02265150-001-05-9

BRD-K02265150-001-15-8

BRN 0832057

BSPBio_000084

BSPBio_002654

C-54133

C17H16ClN3O

CAS-14028-44-5

CCG-39135

CHEBI:2675

CHEMBL1113

CL 67,772

CL 67772

CL-67,772

CL-67772

CPD000058416

CS-4485

CTK8F7751

D00228

DB00543

Defanyl

Demolox

Desmethylloxapin

Desmethylloxapine

DIBENZ(b,f)(1,4)OXAZEPINE, 2-CHLORO-11-(1-PIPERAZINYL)-

Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)-

Dibenzo[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)-

DivK1c_000236

DSSTox_CID_2598

DSSTox_GSID_22598

DSSTox_RID_76652

DTXSID7022598

EINECS 237-867-1

EU-0100116

FT-0659871

GTPL201

HMS1568E06

HMS2089G10

HMS2093N08

HMS2095E06

HMS2231E13

HMS3259G08

HMS3260G14

HMS3370P03

HMS3712E06

HMS500L18

HY-B0991

I06-0520

IDI1_000236

J-007373

KBio1_000236

KBio2_000926

KBio2_003494

KBio2_006062

KBio3_001874

KBioGR_001656

KBioSS_000926

KS-000014ZS

KS-1197

L001293

Lopac-A-129

Lopac0_000116

LP00116

LS-61563

MCULE-9583761109

MFCD00069210

MLS000069371

MolPort-003-666-768

Moxadil

NC00546

NCGC00015004-01

NCGC00015004-02

NCGC00015004-03

NCGC00015004-04

NCGC00015004-05

NCGC00015004-06

NCGC00015004-07

NCGC00015004-08

NCGC00015004-09

NCGC00015004-10

NCGC00015004-11

NCGC00015004-13

NCGC00015004-16

NCGC00023887-03

NCGC00023887-04

NCGC00023887-05

NCGC00023887-06

NCGC00255124-01

NCGC00260801-01

NINDS_000236

NSC-759559

NSC759559

O286

Opera_ID_33

PDSP1_001609

PDSP2_001593

Pharmakon1600-02300161

Prestwick_503

Prestwick0_000102

Prestwick1_000102

Prestwick2_000102

Prestwick3_000102

QWGDMFLQWFTERH-UHFFFAOYSA-N

R63VQ857OT

REGID_for_CID_2170

s4218

SAM002564189

SBI-0050104.P003

SC-79931

SCHEMBL33950

SMR000058416

SPBio_001150

SPBio_002023

Spectrum_000446

Spectrum2_001245

SPECTRUM2300161

Spectrum3_001067

Spectrum4_001218

Spectrum5_001284

SR-01000003001

SR-01000003001-2

SR-01000003001-4

SR-01000003001-6

Tox21_110064

Tox21_110064_1

Tox21_302352

Tox21_500116

UNII-R63VQ857OT

VA10272

Z1551429736

ZINC931

US Patents and Regulatory Information for ASENDIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-003	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for ASENDIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-002	Approved Prior to Jan 1, 1982
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-001	Approved Prior to Jan 1, 1982
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-003	Approved Prior to Jan 1, 1982
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-004	Approved Prior to Jan 1, 1982